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TRANSPLANT CANDIDATES AND SUBSTANCE USE:




Organ transplant candidates are often denied life saving organs on account of
their medical marjuana drug use. Individuals who smoke medicinal marijuana
are typically classified as substance abusers, and ultimately deemed ineligible for
transplantation, despite their receipt of the drug under a physician's supervision
and prescription. However, patients who smoke cigarettes or engage in excessive al-
cohol consumption are routinely considered for placement on the national organ
transplant waiting list. Transplant facilities have the freedom to regulate patient
selection criteria with minimal oversight. As a result, the current organ allocation
system in the United States is rife with inconsistencies and results in disparities in
allocation decisions. This Article reviews the history and underlying rationale of
organ allocation in the United States and the National Organ Transplant Act. It
then examines ill-founded policies regarding transplant candidates who present is-
sues of substance "abuse" compared with substance "use," and the resulting
disparities in waiting-list criteria. In response, a model rule for a national set of
patient selection guidelines is provided. Definitions of terms, distinctions regard-
ing proper patient classification, and protocols for a second chance policy to be
used in the event of a relapse among wait-listed patients are addressed. Finally,
stipulations that require designated abstention periods as well as random drug
screenings in relation to subsequent relisting are also included. This policy distin-
guishes between candidates who present issues of substance use versus substance
abuse. The use of such a model allocation policy will promote equity and scientific
bases in the organ allocation process.
1. INTRODUCTION
In April 2008, Timothy Garon, a Seattle musician, succumbed
to liver failure after a lengthy battle with Hepatitis C.' Garon was
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Director, San Diego Center for Patient Safety, University of California, San Diego School of
Medicine. B.S. Massachusetts Institute of Technology; Ph.D. Harris School of Public Policy,
University of Chicago; M.D. Columbia College of Physicians & Surgeons; J.D. Harvard Law
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1. Medical Marijuana User Dies Without Transplant, KOMONEWS.COM (May 1, 2008),
http://www.komonews.com/news/18475224.html.
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unable to obtain a liver transplant at the University of Washington
Medical Center because of his continued use of medical marijua-
na.2 The hospital agreed to reconsider Garon's application if he
enrolled in a sixty-day drug treatment program. Yet Garon main-
tained his need for the drug and was ultimately disqualified as a
candidate. Garon was also turned down by Harborview Medical
5Center for similar reasons.
Jonathan Simchen is another Seattle resident suffering from re-
nal failure.' Simchen is prescribed marijuana to combat the side
effects of dialysis and regulate his blood pressure.! Like Garon, the
University of Washington Medical Center declined to give Simchen
a transplant because he actively smokes medical marijuana." Virgin-
ia Mason Hospital also rejected Simchen because he would not
agree to a six-month abstention period.
Garon's death and Simchen's denials raise a host of ethical and
legal implications regarding the patient selection criteria used by
organ transplant centers across the nation. Hospitals and organ
procurement organizations are virtually free to set their own
standards with minimal oversight.9 As a result, an individual's
chance of being denied a transplant varies between facilities be-
cause of inconsistent assessment practices.'o
The definition of "substance abuse" is one key area where trans-
plant centers conflict in terms of evaluation. Hospitals often
diverge with regard to the categorization of abusive substances,
length of acceptable sobriety periods, contraindication definitions,
and modes of relapse management." Such deviations result in un-
equal access to transplantation for individuals who use these
substances under a wide array of conditions. 2
2. Gene Johnson, Medical Marijuana Patients Denied a Spot on Transplant List, SEATTLE





6. Marcus Baram, Medical Marijuana User Denied Organ Transplant: Jonathan Simchen,
Who Has Kidney Failure, Is Latest Example of User Turned down for Organ Transplants, ABC NEWS
(May 20, 2008), http://abcnews.go.com/Health/story?id=4893948&page=1.
7. Johnson, supra note 2.
8. Baram, supra note 6.
9. See Ingrid Kinkopf-Zajac, Assessing Patient Compliance in the Selection of Organ Trans-
plant Recipients, 6 HEALTH MATRIX:J. L.-MED. 503, 512-13 (1996).
10. See Richard S. Mangus et al., Wide Disparity in Substance Use Policies for Liver
Transplant Candidates at U.S. Centers (Oct.-Nov. 2008) (poster presentation at American
Association for the Study of Liver Disease) (on file with authors); see also Kinkopf-Zajac,
supra note 9, at 513.
11. See Mangus et al., supra note 10.
12. See id.
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The disparate treatment of organ transplant candidates is evi-
dent when policies on medical marijuana use are examined. Many
centers will reject individuals who regularly smoke medical mariju-
ana.13 Most physicians base such denials on the possibility of
aspergillosis, a serious infection that may occur if marijuana is used
after surgery.14 Others feel smoking marijuana causes cognitive dis-
tortions, which can lead to patient noncompliance and threaten
organ vitality following transplantation.15 Although medical evi-
dence suggests marijuana-induced health problems can affect
recovery post-transplantation, there are no data that show marijua-
na has a direct toxic effect on allografts.'6
In contrast, a majority of transplant facilities will routinely con-
sider patients who exhibit signs of alcoholism or smoke cigarettes
on a daily basis." The preferential treatment given to patients who
consume these clearly harmful and non-clinically beneficial sub-
stances is contrary to the equitable underpinnings of the U.S. organ
allocation system. Ongoing shortages in organ supplies have led to
some distribution strategies that result in biased allocations.'8 In the
area of substance use and abuse, transplant refusals occur despite
the comparative absence of risk factors that warrant exclusion.
Unfortunately, the lack of a single rational paradigm for patient
selection can lead to premature elimination, or even death, among
individuals in need of life-saving organs. Current systems used to
establish such rules are convoluted, are often arbitrary, and do not
reflect sound medical policy. Patients who use marijuana under
supervised medical care are especially vulnerable within this con-
text, as current methodologies work to inhibit their chances of
procuring effective treatment. If this situation remains un-
addressed, viable candidates will continue to be denied access to
life-saving organs.
This Article delineates the issue and provides a model guideline
for wait-listing practices undertaken by hospitals for patient selec-
tion criteria. Section II provides a background on current U.S.
13. SeeJohnson, supra note 2.
14. See Katrina A. Bramstedt et al., Shopping for a Transplant: When Noncompliant Patients
Seek Wait Listing at Multiple Hospitals, 14 PROGRESS IN TRANSPLANTATION 217, 218 (2004).
15. See id. at 218-19.
16. Id. An "allograft" is "[t]he transplant of an organ or tissue from one individual to
another of the same species with a different genotype." Definition of Allograft, MEDI-
CINENET.COM, http://www.medterms.com/script/main/art.asp?articlekey=30941 (last
updated Feb. 21, 2004).
17. See Mangus et al., supra note 10.
18. See Dulcinea A. Grantham, Comment, Transforming Transplantation: The Effect of the
Health and Human Sernces Final Rule on the Organ Allocation System, 35 U.S.F. L. REV. 751, 751-
52 (2001).
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organ allocation practices, as governed by the National Organ
Transplant Act ("NOTA"). Despite its passage, the inconsistencies
in transplant center policies for recipient selection, and the rip-
pling effects it can have on listing status, create disparities and the
very circumstances that NOTA was designed to address.
Section III examines how institutional waiting list policies are
highly inconsistent and inequitable based on substance use and
abuse, second chance listing, and inappropriate science. Specifical-
ly, the effects tobacco and marijuana have on organ recipients are
analyzed to illustrate the disconnect between science and treat-
ment of these transplant candidates.
A set of model guidelines for transplant wait-listing, and alloca-
tion is then provided in Section IV. This proposal specifically focuses
on resolving discrepancies in contradicting taxonomies, expanding
the depth of candidate review, and reconciling interpretive dilem-
mas surrounding the definition of substance abuse versus substance
use. A detailed plan for policy decision-making that calls for physi-
cian discretion and interdisciplinary collaboration is then
delineated. Finally, in Section V, we call for a focus on science in
transplantation policy to ensure equity for patient access to organs.
II. THE PATHWAY TO DISPARITY
A. The National Organ Transplantation Act and the
Organ Procurement and Transplantation Network
During the mid-1980s, a great deal of public discord surrounded
the organ rationing techniques utilized in the United States. 9 At
the time, the country lacked a single authority for organ distribu-
tion.20 Individual transplant centers were free to set their own
procurement criteria, which led to organ hoarding, varying and
inconsistent standards, and rifts in sharing practices within the
transplant community. 2 Distribution tactics that favored the
wealthy and foreign nationals over American citizens were also
common.22 Patients with limited financial resources and minimal
19. See Kinkopf-Zajac, supra note 9, at 509.
20. See Grantham, supra note 18, at 754.
21. SeeJed Adam Gross, Note, E Pluribus UNOS: The National Organ Transplant Act and
Its Postoperative Complications, 8 YALEJ. HEALTH POL'Y L. & ETHics 145, 148-49 (2008).
22. See Kinkopf-Zajac, supra note 9, at 509; see also Gross, supra note 21, at 149.
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health care coverage ultimately turned to the government for help
with donor location and funding.23
In response to these issues, Congress enacted the National Or-
gan Transplant Act ("NOTA") in 1984. NOTA was designed to
streamline the organ allocation process and provide Americans
with a fortified regime for transplantation." This legislation also
attempted to promote an equitable system for organ allocation
based on sound medical criteria.
Among other things, NOTA established a task force on organ
transplantation whose members were to be appointed by the Secre-
tary of Health and Human Services.2 ' After an extensive
investigation, this task force recommended the creation of a na-
tional Organ Procurement and Transplantation Network
("OPTN") .28 The task force also delineated an agenda for organ
procurement that required patient selection strategies to be based
on sound medical criteria.2 Factors to be considered included an
individual's need, likelihood of success, and time spent on the wait-
ing list.30 Moreover, the task force emphatically advised against
weighing an individual's social worth when rendering such deci-
*31sions.
B. OPTN, OPOs, UNOS, and Allocation
OPTN currently maintains the national waiting list for individu-
als in need of organ transplants. OPTN also regulates allocation
standards that organ procurement organizations ("OPOs") must
follow throughout the transplantation process. 33 The United Net-
work for Organ Sharing ("UNOS") is the non-profit organization
contracted to administer OPTN." UNOS compiles data on all
23. SeeNeal R. Barshes et al.,Justice, Administrative Law, and the Transplant Clinician: The
Ethical and Legislative Basis of a National Policy on Donor Liver Allocation, 23 J. CONTEMP.
HEALTH L. & POL'Y 200, 208 (2007).
24. See Pub. L. No. 98-507, 98 Stat. 2339 (codified as amended at 42 U.S.C. §§ 273, 274,
274a-274e (2006)).
25. See Grantham, supra note 18, at 754.
26. See 42 U.S.C. § 273(b) (3) (E).
27. See National Organ Transplant Act §§ 101-105, 98 Stat. 2339-42.
28. See Kinkopf-Zajac, supra note 9, at 510. The Network was created by 42 U.S.C.
§ 274(a). See generally 42 U.S.C. § 274.
29. See Barshes et al., supra note 23, at 213.
30. See id.
31. Id.
32. See 42 U.S.C. § 274(b) (2) (A) (i)-(ii).
33. See id. § 274(b) (2) (B).
34. History of OPTN, ORGAN PROCUREMENT & TRANSPLANTATION NETWORK,
http://optn.transplant.hrsa.gov/optn/history.asp (last visited Dec. 28, 2010).
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transplants that occur in the United States and facilitates organ
matching and placement among candidates. UNOS has also es-
tablished policies that promote equitable allocation to individuals
on the national waiting list. 6
OPO membership within UNOS is divided into eleven geo-
graphic areas throughout the country." Once an OPO secures an
organ, UNOS is contacted, and donor/recipient information is
entered into a national database, called UNet.3" A match is then
conducted for the organ.3 9 The search results for potential candi-
dates are ranked in accordance with objective medical criteria,
such as blood type, tissue size, and medical emergency.40 The time
a patient has spent on the waiting list and the distance between
donors and recipients are also considered during the allocation
process.' Each organ also has its own specific criteria.
The match list of potential recipients is used to identify the
43highest ranked recipient, who is then offered the organ. That pa-
35. About Us, UNITED NETWORK FOR ORGAN SHARING, http://www.unos.org/about/
index.php (last visited Dec. 28, 2010).
36. See Douglas J. Norman, UNOS: The Development, Objectives and Future of The National
Organ Transplant Network, NEW DEV. TRANSPLANTATION MED., Spring 1994, available at
http://www.centerspan.org/pubs/news/sp94a.htm ("UNOS has formulated policies to
ensure equitable organ allocation to patients who are registered on the national patient
waiting list. These policies forbid favoritism based on political influence, race, sex, or finan-
cial status, relying instead on sound medical and scientific criteria.").
37. See Regions, ORGAN PROCUREMENT & TRANSPLANTATION NETWORK, http://optn.
transplant.hrsa.gov/members/regions.asp (last visited Dec. 28, 2010).
38. See Organ Allocation, UNITED NETWORK FOR ORGAN SHARING, http://www.
unos.org/donation/index.php?topic=organ-allocation (last visited Dec. 28, 2010).
39. See id.
40. See How the Transplant System Works, UNITED NETWORK FOR ORGAN SHARING,
http://www.unos.org/donation/index.php?topic=fact-sheet_1 (last visited Dec. 28, 2010).
Overall allocation protocol ... [based on] degrees of medical urgency ... [are] con-
sistent with the following factors[:] . . . sound medical judgment, best use of donated
organs, preservation of physician judgment in declining organ offers or use for the
potential recipient, suitability for the specific organ ... , avoidance of organ waste
and futile transplants and promotion of candidate access to transplantation and effi-
cient management of organ placement, periodic review and revision as appropriate,
and disassociation with candidate's place of residence or place of listing as feasible in
light of the previously listed elements.
OPTN Evaluation Plan, ORGAN PROCUREMENT & TRANSPLANTATION NETWORK, 11-5 to -6
(Sept. 30, 2010), http://optn.transplant.hrsa.gov/SharedContentDocuments/Evaluation
Plan_508_093010.pdf.
41. See How the Transplant System Works, supra note 40.
42. See id.
43. See id.
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tient's local transplant center is then contacted.4" If accepted, the
organ is transported, and surgery is scheduled.
C. The Nature of Organ Procurement and Allocation
OPTN's administrative efforts have been nominally successful
since its creation.4 ' However, challenges remain with respect to ac-
tual allocation due to the scarcity of organs available for
transplants. For example, in 2007, there were 28,369 patients that
underwent organ transplants. Yet, that same year, 52,860 individ-
uals were added to the national waiting list.4 Approximately 7,295
candidates died while waiting for a transplant in 2007." Given the
scarcity of organs, patients who will benefit most from transplanta-
tion should theoretically be given priority.5 0
D. Geographic Disparities
Yet disparities abound. For example, geographic location can
weigh heavily against a patient's ability to receive an organ. The
median wait time for Region 5 Heart Status 1A candidates from
2003 to 2004 was twenty-nine days.5' In contrast, the median wait
44. See id.
45. See id. If the organ is turned down, the next potential recipient's transplant center
on the match list is contacted and the process repeats itself until the organ is accepted. Cf
id.
46. See Liliana M. Kalogjera, New Means of Increasing the Transplant Organ Supply: Ethical
and Legal Issues, HUM. RTs., Fall 2007, at 19, 20 (noting that organ shortage continues to
grow despite multifaceted efforts to increase the transplant organ supply); see alsojohn M.
Coombes &James F. Trotter, Development of the Allocation System for Deceased Donor Liver Trans-
plantation, 3 CLINICAL MED. & RES. 87, 88 (2005); Gross, supra note 21, at 147-48.
47. Transplants by Donor Type, ORGAN PROCUREMENT & TRANSPLANT NETWORK,
http://optn.transplant.hrsa.gov/latestData/step2.asp (select "Transplant" from the "Cate-
gory" list; then follow "Transplants by Donor Type" hyperlink) (last updated Dec. 17, 2010).
48. Waiting List Additions by UNOS Status at Listing by Listing Year, ORGAN PROCUREMENT
& TRANSPLANT NETWORK, http://optn.transplant.hrsa.gov/latestData/step2.asp (select
"Waiting List Additions" from the "Category" list; then follow "Waiting List Additions by
UNOS Status" hyperlink) (last updated Dec. 17, 2010).
49. Death Removals by UNOS Status by Year, ORGAN PROCUREMENT & TRANSPLANT NET-
WORK, http://optn.transplant.hrsa.gov/latestData/step2.asp (select "Waiting List Removals"
from the "Category" list; then follow "Death Removals by UNOS Status by Year" hyperlink)
(last updated Dec. 17, 2010).
50. See Bramstedt etal., supra note 14, at 217.
51. Median Waiting Time for Region 5, ORGAN PROCUREMENT & TRANSPLANT NET-
WORK, http://optn.transplant.hrsa.gov/latestData/stateData.asp?type=region (select
"Region 5"; then select "Median Waiting Time" from the "Category" list; then follow "Wait-
ing Time by UNOS Status at Listing" hyperlink) (last updated Dec. 17, 2010). Region 5
includes California, Arizona, Nevada, Utah, and New Mexico. See Regions, supra note 37.
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time for Region 1 Heart Status 1A candidates during this same peri-
od was fifty-four days." From 2003 to 2004, Region 5 Liver Status 1
patients waited an average of nine days for a transplant.3 In contrast,
Region 1 Liver Status 1 patients waited an average of thirty-seven
days." Thus, candidates in the northeast have a greater chance of
succumbing to liver and/or heart failure than candidates on the
west coast.
Even within regions, discrepancies in wait time are also present
among local transplant centers within a single state. For example,
689 people are wait-listed for a kidney transplant at Cedars-Sinai
Medical Center in Los Angeles, California. Approximately twenty
patients are expected to wait less than thirty days before receiving a
kidney.5 6 Sixty-seven candidates are estimated to receive a kidney
within the next thirty to ninety days.
Yet over 5000 patients are on the waiting list for a kidney trans-
plant at the University of California San Francisco Medical
Center.5 ' Roughly ninety candidates are anticipated to receive a
kidney within thirty days.59 Almost 151 patients will wait between
thirty and ninety days before obtaining a transplant.6 Accordingly,
candidates in southern California are more likely to receive a kid-
ney transplant within the next ninety days, compared to individuals
in northern California.
52. Median Waiting Time for Region 1, ORGAN PROCUREMENT & TRANSPLANT NET-
WORK, http://optn.transplant.hrsa.gov/latestData/stateData.asp?type=region (select
"Region 1"; then select "Median Waiting Time" from the "Category" list; then follow "Wait-
ing Time by UNOS Status at Listing" hyperlink) (last updated Dec. 17, 2010). Region I
includes Connecticut, Maine, Massachusetts, New Hampshire, and Rhode Island. See Regions,
supra note 37.
53. Median Waiting Time for Region 5, supra note 51.
54. Median Waiting Time for Region 1, supra note 52.
55. Kidney Transplant Waitlist at Cedars-Sinai Medical Center, ORGAN PROCUREMENT
& TRANSPLANT NETWORK, http://optn.transplant.hrsa.gov/latestData/stateData.asp?type=
center (select "California"; then select "CACS-TX1 Cedars-Sinai Med Center" from "Center"
list; then select "Waiting List" from "Category" list; then select "Candidates" from "Count"
options; then follow "Organ by Waiting Time" hyperlink) (last updated Dec. 17, 2010) (all




58. Kidney Transplant Waitlist at UC San Francisco Medical Center, ORGAN PRO-
CUREMENT & TRANSPLANT NETWORK, http://optn.transplant.hrsa.gov/latestData/
stateData.asp?type=center (select "California"; then select "CASF-TX1 Univ of CA San Fran-
cisco Med Ctr" from "Center" list; then select "Waiting List" from "Category" list; then select
"Candidates" from "Count" options; then follow "Organ by Waiting Time" hyperlink) (last
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There are several explanations for disparities based on geo-
graphic location. Despite NOTA and OPTN, a hospital's and an
OPO's size, procurement policies, and procurement practices can
-61lead to differences in candidate prioritization. In addition,
wealthier patients in less densely populated areas often have mini-
mal wait times, compared to those in larger communities.12
Further, competition for organs tends to be greater in more dense-
ly populated areas. Some facilities may also have trouble
identifying and obtaining consent from potential donors.64
In sum, a wide array of factors, including a hospital and OPO's
procedural operations, patient wealth, and geographic population
density can all affect the length of time candidates spend waiting
for an organ. Consistency is not an attribute easily applied to organ
allocation efforts in the United States. Hence, despite NOTA, equi-
table distribution of organs for transplants still remains an elusive
goal.
E. Disparities
Hospital and OPO policies, geography, and wealth are not the
only hurdles faced by potential organ recipients. An individual's
probability of merely becoming listed fluctuates between transplant
centers throughout the country. 5 Thus, beyond actual organ allo-
cation, simply obtaining a spot on the national waiting list is rife
with inconsistencies.
One reason for the lack of homogeneity in patient selection tac-
tics may be attributed to the absence of federal oversight. National
directives tend to establish restrictions that govern the medical
care used to determine transplant candidate selection criteria.
For example, state programs or facilities that receive federal fund-
ing cannot exclude disabled individuals solely on the basis of their
disabilities.67
While this provision applies to hospitals that receive government
subsidies, it provides little structure to the formation and imple-
mentation of patient selection criteria. Other federal legislation




65. See Mangus et al., supra note 10; see also Kinkopf-Zajac, supra note 9, at 513.
66. See Developments in the Law: Medical Technology and the Law, 103 HARV. L. REv. 1519,
1630-31 (1990) [hereinafter Developments].
67. See Rehabilitation Act of 1973 § 504, 29 U.S.C. § 794(a) (2006).
68. See id. § 794(b) (3) (A) (ii).
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that addresses procurement practices of hospitals and OPOs is
considered advisory, not mandatory.69
Hospitals and OPOs are also free to apply their own patient
evaluation modalities for waiting list placement.7o For example,
Ochsner Health System in New Orleans avoids detailing a set list of
contraindications that would otherwise preclude acceptance of po-
tential kidney or pancreas recipients.7 1 Instead, Ochsner indicates
that "[t] he list of absolute and relative contradictions for Kidney or
Kidney/Pancreas transplant is continually evolving as [the hospi-
tal's] experience with certain pre-existing conditions and diseases
grows. The only specific contraindications Ochsner feels would
inhibit allocations are excessive body mass index, active malignan-
cies, and/or active infection.
In contrast, Henry Ford Hospital in Detroit lists a host of contra-
indications for kidney and pancreas recipients. In addition to
active malignancies and infection, potential candidates may be de-
nied for substance dependency, non-compliance, inadequate
support system, and an inability to adhere to post-transplantation
immunosuppression regimens and follow-up care.
Because of the significant variations in listing assessments, many
candidates may be rejected by one center and still be accepted at
another facility.76 Yet, the option of selecting multiple transplant
69. See Benjamin Mintz, Analyzing the OPTN Under the State Action Doctrine-Can UNOS's
Organ Allocation Criteria Survive Strict Scrutiny?, 28 CoLUM.J.L. & Soc. PROBs. 339, 348 (1995).
70. See Kinkopf-Zajac, supra note 9, at 513.
71. Kidney and Pancreas Transplant Indications and Contraindications, OCHSNER
HEALTH Sys., http://www.ochsner.org/programs/transplant-kidneyindications/ (last
visited Dec. 28, 2010).
72. Id.
73. See id.
74. See Are You a Transplant Candidate?, HENRY FoRD HosP.,
http://www.henryfordhealth.org/body.cfm?id=49331 (last visited Dec. 28, 2010).
75. See id. The differences in contraindication classification exemplify how hospitals
vary in terms of patient listing evaluation. Here, both Ochsner and Henry Ford view kidney
and pancreas candidates with active malignancies and/or infections as questionable in terms
of listing potential. Yet issues of substance dependency, non-compliance, or an inability to
adhere to follow-up care routines may be seen as contraindicative at Henry Ford, but not
Ochsner, if surrounding circumstances support listing status.
76. See Kinkopf-Zajac, supra note 9, at 513 ("'Each local transplant team formulates
and applies its own criteria for waiting-list placement and patient selection.' For this reason,
criteria used generally 'vary from center to center, and a candidate rejected at one center
may be accepted at another.'" (quoting Developments, supra note 66, at 1630-31 & n.1 10)). A
recent case study tracked a liver candidate who simultaneously gained listing status at an east
coast hospital and two Midwestern facilities. The patient's marijuana use prompted him to
seek multiple listings because of how each hospital classified individuals who consumed the
drug. This patient was placed on hold by the east coast hospital after failing multiple drug
tests, but was later relisted. The same patient, however, was deferred at an Ohio hospital and
recommended for chemical dependence treatment because he lacked active participation in
676 [VOL. 44:3
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centers is not open to everyone. Patients are often limited to seek-
ing admittance at facilities within their health maintenance
organizations." Candidates who can afford to go through the eval-
uation process several times are more likely to achieve dual listings
than patients limited to hospitals within their insurance networks."'
F Affluence
Affluence is a factor that can improve a patient's chances of
gaining waiting list status. For instance, Yankee's legend Mickey
Mantle received a liver transplant within weeks of being placed on
a waiting list.79 Despite years of battling alcohol abuse, liver cancer
and hepatitis C, Mantle was released from the hospital with a new
liver exactly one month after being approved for a transplant.8 0
Although Mantle's blood type and physical condition made him
the number one liver candidate within his geographic region, his
financial state may have tipped the scales in his favor." Organ re-
cipients absorb hundreds of thousands of dollars in medical bills
within the first year of care following transplantation. Newly ap
proved candidates must demonstrate their ability to finance such
expenses, which include travel costs and anti-rejection drugs.83 Giv-
en Mantle's financial state, his chances of covering anticipated
medical bills may explain why he received a liver so quickly.
Despite a successful transplant, Mantle succumbed to cirrhosis-
induced liver cancer two months after surgery. Mantle's cancer
a recovery program. At this facility, detoxification was a prerequisite for listing status. See
Bramstedt et al., supra note 14, at 218.
77. See Gina Kolata, Getting on a Transplant List Is the First of Many Hurdles, N.Y. TIMES,
June 10, 1995, at Al, available at http://www.nytimes.com/1995/06/10/sports/getting-on-a-
transplant-list-is-the-first-of-many-hurdles.html.
78. See id.
79. See Allen R. Myerson, Mantle Is Released from Hospital, N.Y. TIMEs, June 29, 1995, at
B12, available at http://www.nytimes.com/1995/06/29/sports/baseball-mantle-is-released-
from-hospital.html.
80. Id. Some feel Mantle perpetuated his own health problems. Had he abstained from
drinking, his liver cancer may have laid dormant for decades. Mantle's liver transplant illus-
trates an ethical dilemma that plagues the transplant community regarding whether patients
who actively contribute to their diseases should receive life-saving organs, despite their self-
destructive tendencies. See Gina Kolata, Transplants, Mortality and Mickey, N.Y. TIMEs, June 11,
1995, at E5, available at http://www.nytimes.com/1995/06/11/weekinreview/the-nation-
transplants-morality-and-mickey.html.
81. See Kolata, supra note 77.
82. See id.
83. See id.
84. See Lawrence K. Altman, The Death of a Hero; Mantle's Cancer 'Most Aggressive'
His Doctors Had Seen, N.Y. TIMEs, Aug. 14, 1995, at C5, available at
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spread to both lungs five weeks following the transplant and metas-
tasized to his abdomen just before he died."
While doctors claim Mantle's cancer showed no signals of pro-
gression prior to surgery, critics believe otherwise.86  Most
individuals with primary liver cancer evince signs the cancer has
spread to areas outside the liver when the disease is first detected."'
Moreover, relatively few patients with rare types of liver cancer re-
spond to transplantation.""
Those with cirrhosis-induced liver cancer are seldom viewed as
prospective candidates for liver transplants. 9 Most often, such pa-
tients' prognoses are extremely poor.90 In addition to the scarcity of
donor organs, immunosuppression regimes can interfere with the
body's ability to combat cancer cells."' Even if a candidate has mi-
croscopic cancer cells before surgery, these malignances enlarge
after transplantation." The chances a new liver will bring lasting
cures to patients with this type of cancer are minimal. Mantle's
transplant, and subsequent death, further illustrates this point.
Steve Jobs, founder and CEO of Apple, is yet another example
of how financial status can facilitate waiting list placement. Jobs was
diagnosed with pancreatic cancer in 2004"' and had a cancerous
tumor removed from his pancreas that same year.95 In some cases,




86. See Jane E. Brody, Questions Are Raised on Mantle Transplant, N.Y. TIMES, Aug. 2,




89. See id. Hepatocellular cancer and cirrhosis are related. Cirrhosis is an abnormal
liver condition characterized by irreversible scarring of the liver. Alcohol consumption is
one of cirrhosis' many causes. Definition of Cirrhosis, MEDICINENET.COM,
http://www.medterms.com/script/main/art.asp?articlekey=2740 (last updated Mar. 26,
1998). Hepatocellular carcinoma is cancer of the liver. People who have cirrhosis are more
likely to get primary adult liver cancer. Definition of Hepatocellular Carcinoma, MEDI-
CINENET.COM, http://www.medterms.com/script/main/art.asp?articlekey=18505 (last
updated Apr. 2, 2002).




94. See Lauren Cox, Steve jobs' Reported Liver Transplant Stirs Debate, ABC NEWS (June 23,
2009), http://abcnews.go.com/Health/Economy/story?id=7902416.
95. See Philip Elmer-DeWitt, Inside Steve Jobs' Liver Transplant, CNNMONEY.COM (June
20, 2009, 7:31 AM), http://tech.fortune.cnn.com/2009/06/20/inside-steve-jobs-liver-
transplant/.
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necessitates the need for a transplant.9 6 Thus, it was no surprise
when Jobs underwent a liver transplant in March 2009 at a hospital
in Memphis, Tennessee.
A great deal of controversy soon followed. Many liver transplant
candidates consider Tennessee a Mecca because it harbors one of
the shortest waiting lists in the country.9 8 Contrast California, where
Jobs resides, which maintains one of the longest lists in the United
States."9 Critics believe Jobs was able to reduce his wait time be-
cause he could afford to engage in multiple listing tactics at
transplant hospitals outside his home state, an option that only ex-
ists for the wealthy.'00
A patient's notoriety can also increase his or her probability of
being admitted to a waiting list. Former governor of Pennsylvania
Robert P. Casey received a heart and liver transplant while in of-
fice.o' Casey underwent surgery hours after he was placed on a
waiting list.'o2 When Casey received the organs, the median wait
time for a liver transplant in his region was sixty-seven days."' Heart
recipients waited an average of 198 days.'0 4 But for the former gov-
ernor, it was less than twenty-four hours.
While the effects of organ failure are the same for all candidates
vying for listing status, their chances of actually receiving a trans-
plant remain uneven. Lack of federal oversight, coupled with the
ability of hospitals and OPOs to set their own standards for organ
allocation, patient selection, and waiting list criteria have led to
preferential treatment of the rich and famous-a situation that re-
flects the very circumstances before NOTA was passed and that it
was designed to address.
96. See Cox, supra note 94.
97. Id.
98. SeeJohn Lauerman & Connie Guglielmo, jobs Travel to Transplant Mecca Shows Sys-
tem Flaws, BLOOMBERG (June 29, 2009, 4:31 PM), http://www.bloomberg.com/apps/news?
pid=20601103&sid=au6imqRi7UHE.
99. See id.
100. See Cox, supra note 94.
101. See Irvin Molotsky, Former Governor Robert P. Casey Dies at 68; Pennsylvania Democrat
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III. IMPACT: INSTITUTIONAL ORGAN POLICIES AND
SUBSTANCE USE AND ABUSE
A. Inconsistency: Abstinence and "Second Chance" As Examples
The autonomy OPOs and hospitals have in formulating selec-
tion criteria has led to a striking divergence in selection tactics,
especially with regard to individuals who present issues of sub-
stance use and abuse. These differences range from absence of any
policies to those that do not bear scrutiny when assessed from a
medical policy perspective. The lack of official guidelines in this
area is of grave concern given the nature of substance abuse and
the potential repercussions it can have on a person's overall quality
of health, as well as survival with the transplanted organ.'os
Approximately 2.5 million deaths worldwide are attributable to
alcohol.'06 For example, alcoholic liver disease is one of the most
common indicators for liver transplantation among patients in the
United States and Europe. o0 It is therefore a critical area to have
clear standards on its use and abuse to ensure appropriate alloca-
tion and candidate listing for transplantation potential.
Yet how alcohol is addressed represents one of the most dra-
matic examples of variation in transplant policy.08 A recent survey
assessed variations in substance use policies for liver transplant
centers across the United States.'" Ninety-six U.S. adult liver trans-
105. Organ transplantation has become a common treatment strategy for patients suf-
fering from diseases caused by prolonged substance abuse. Yet, many are concerned that
substance abusers who receive these life-saving organs will return to drug or alcohol use
after surgery. Such behavior may have harmful effects on graft function, organ health, or
survival rates. However, available data reflects inconsistencies with respect to how often pa-
tients return to substance abuse post-transplantation, and what predictors can be used to
identify such outcomes. See Mary Amanda Dew et al., Meta-Analysis of Risk for Relapse to Sub-
stance Use After Transplantation of Liver or Other Solid Organs, 14 LIVER TRANSPLANTATION 159,
159-60 (2008).
106. Alcohol Abuse Facts and Figures, WHO, http://www.who.int/substanceabuse/
facts/alcohol/en/index.html (last visited Dec. 28, 2010).
107. SeeDew etal., supra note 105, at 159.
108. No clear agreement exists among medical professionals regarding how long a pa-
tient must abstain from alcohol use prior to undergoing a transplant. Some critics feel that
arbitrary abstention periods should not be set for patients suffering from alcohol-induced
cirrhosis. This belief is based on the nature of cirrhosis, which can cause unexpected infec-
tion and/or death among cirrhotics. These risk factors make it difficult to determine an
accurate life span or an ideal time to perform surgery on such patients. As a result, many
patients have died waiting for a liver because they were forced to fulfill criteria for prede-
termined sobriety periods. See Lawrence K. Altman, Doctor's World; A Question of Ethics: Should
Alcoholics Get Transplanted Livers?, N.Y. TIMEs, Apr. 3, 1990, at C3, available at http://www.
nytimes.com/1990/04/03/science/doctor-s-world-a-question-of-ethics-should-alcoholics-get-
transplanted-livers.html.
109. Mangus et al., supra note 10.
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plant centers performing ten or more annual liver transplants were
identified and contacted through UNOS."o Of the responding cen-
ters, 16% had no written policies on substance abuse."'
Those centers with written initiatives required 100% alcohol ab-
stention prior to surgery."' But such abstention periods varied. For
instance, 81% of responding centers had six-month sobriety peri-
ods."1 Yet 6% of hospitals had policies that ranged from six to twelve
months.114 The remaining facilities had abstinence requirements
that were less than six months or were determined on a case-by-case
basis."'
Other discrepancies were also present. Roughly 74% of the re-
sponding transplant centers carved out exceptions to requisite
abstention periods for candidates with cirrhosis-induced liver can-
cer."6 Approximately 80% of responding liver transplant centers
also have second-chance policies for individuals who drank alcohol
after a previous agreement to cease consumption."7
The above variations, coupled with "case-by-case" analyses, create
significant room for alterations in candidate priority within and
across transplant facilities. Thus, some individuals who continue to
drink in the months leading up to surgery may still be able to re-
ceive a liver despite their continued alcohol consumption, while
others face lengthy abstention periods, and even death, in the







116. See id. This exception is shocking, as a leading cause of cirrhosis is alcoholism. See
Hepatocellular Carcinoma, MEDLINEPLUS, http://www.nlm.nih.gov/medlineplus/ency/
article/000280.htm (last updated Dec. 15, 2010).
117. See Mangus et al., supra note 10. For example, Loma Linda University Medical Cen-
ter in southern California has implemented a second chance policy for patients wait-listed
for liver transplants. Candidates must initially submit to a six-month abstention period and
are subject to urine and drug screening. If a patient tests positive for either drugs or alcohol,
they must return to their assigned social worker and complete six months of AA before they
can be relisted. However, none of the candidates at Loma Linda who were subjected to a
second six-month abstention period made it back on the list. Telephone Interview with
Jennifer Stuart, Transplant Coordinator, Loma Linda Univ. Med. Ctr. (Jan. 18, 2010) (inter-
view notes on file with author).
118. Tobacco is similar to alcohol. Tobacco continues to cause the most damage to
physical health on a global scale. Tobacco Abuse Facts and Figures, WHO,
http://www.who.int/substance abuse/facts/tobacco/en/index.html (last visited Dec. 28,
2010). However, despite the clear relationship between poor health and tobacco use, only
31% of the surveyed hospitals required applicants to completely abstain from tobacco use
prior to surgery. See Mangus et al., supra note 10. Indeed, among the same facilities, only 6%
require patients with lung disease to stop smoking cigarettes, while 63% permit continued
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B. Marijuana and Cigarettes: Lack of Rational
Foundation for Transplant Policy
However, one of the greatest areas of transplantation regulation
that lacks medical and policy foundation relates to medicinal mari-
juana use and cigarette smoking. The evidence and breadth of
cigarette smoking harm is overwhelming."' Among other things,
tobacco use causes 8.8% of deaths worldwideo and "kills more
than 430,000 U.S. citizens each year-more than alcohol, cocaine,
heroin, homicide, suicide, car accidents, fire, and AIDS com-
bined." '2 It also impacts virtually every human organ and affects
wound healing. I
Yet candidates who smoke cigarettes are much more readily
accepted by liver transplant centers than those who use marijua-
na.'2 3 In contrast to cigarettes, which have lethal implications and
no medicinal effects, marijuana has been shown to have signifi-
cant benefits associated with its health care use"' and limited
tobacco use in such cases. See id. These contradictory, but otherwise permissible actions give
patients mixed signals as to what constitutes acceptable behavior.
119. See WORLD HEALTH ORG., WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC,
2008: THE MPOWER PACKAGE 14-18 (2008), available at http://www.who.int/tobacco/
mpower/mpower-reportfull _2008.pdf. The Family Smoking Prevention and Tobacco Con-
trol Act, which was signed into law by President Obama in June 2009, lends additional
support to the fact that tobacco significantly threatens public health and the well-being of
our nation's children. Among other things, the Act places severe restrictions on the market-
ing of tobacco products to minors, to reduce the number of minors who become addicted
to cigarettes. According to Congress, such measures stand to reduce health care costs relat-
ed to Americans who develop smoking habits in their youth by roughly $75 billion and save
three million of these individuals from premature death due to tobacco-induced disease. See
Family Smoking Prevention and Tobacco Control Act, Pub. L. No. 111-31, § 2(14), 123 Stat.
1776, 1777 (2009).
120. See Tobacco Abuse Facts and Figures, supra note 118.
121. Drug Abuse and Addiction Research: The Sixth Triennial Report to Congress, NAT'L INST.
ON DRUG ABUSE, http://archives.drugabuse.gov/STRC/Forms.html#Nicotine (last visited
Dec. 28, 2010) (emphasis added).
122. SeeJUDITH MACKAY & MICHAEL ERIKSEN, THE TOBACCO ATLAS 33 (2002), available
at http://www.who.int/tobacco/en/atlas9.pdf.
123. See Mangus et al., supra note 10 (noting that 31% of liver transplant centers affirm-
atively oppose tobacco use, while marijuana use is explicitly prohibited in 88% of such
facilities).
124. See, e.g., R. Gorter et al., Dronabinol Effects on Weight in Patients with HIVInfection, 6
AIDS 127, 127 (1992) (noting that medical marijuana positively impacts weight in HIV pa-
tients with wasting syndrome); Mary McCabe et al., Efficacy of Tetrahydrocannabinol in Patients
Refractory to Standard Antiemetic Therapy, 6 INVESTIGATIONAL NEW DRUGS 243, 243 (1988)
(noting usefulness of medical marijuana to curb nausea in patients failing on other anti-
nausea medications); Vincent Vinciguerra et al., Inhalation Manjuana as an Antiemetic for
Cancer Chemotherapy, 85 N.Y. ST. J. MED. 525, 527 (1988) (noting that medical marijuana
effectively treats nausea associated with chemotherapy). Recent legislative activity shows how
some states support marjuana use in certain contexts. On January 11, 2010, New Jersey
became the fourteenth state to legalize marijuana for medicinal purposes. New Jersey is
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negative effects. 2 5
Like those for alcohol, transplantation policy and procedures re-
lated to marijuana use are highly variable. Almost 90% of liver
transplant centers surveyed specifically proscribe marijuana use,
while 13% do not routinely test for this substance. 26 Further, nearly
77% of responding facilities have implemented second chance pol-
icies for wait-listed patients who tested positive for marijuana. 2 7 In
effect, patients face either possible drug tests and categorical deni-
als or minimal screening and an additional opportunity to
maintain listing status in the event of a failed drug test.
Transplantation access and policy variability regarding medical
marijuana are complicated by policy developments that implicate
illegal drug use. For example, all liver transplant hospitals surveyed
exclude patients who use "illicit" substances.'2" Even here, requisite
sobriety periods vary: some facilities require just one negative
screen (which may be achieved with only a few months of sobriety),
while others require a full year.'2
In the case of marijuana, the drug remains illegal under federal
statute.10 But fourteen states have legalized marijuana use for me-
dicinal purposes.'2 ' This creates the anomaly that some users may
be able to obtain access to transplant organs after one negative
screen, while others using the drug under a physician's care may
be summarily rejected for organ transplant allocation and listing.
among a handful of east coast states to do so. While the availability of medical marijuana is
limited to a narrowly defined set of illnesses, both voters and lawmakers felt such legislation
was necessary to improve the quality of life for citizens who are in extreme pain. David Ko-
cieniewski, New Jersey Vote Backs Marijuana for Severely Ill: Both Houses Pass Bill: Gov. Corzine to
Sign It-State to Be 14th to Legalize Drug, N.Y. TIMES, Jan. 12, 2010, at Al, available at
http://www.nytimes.com/2010/01/12/nyregion/12marijuana.html.
125. See, e.g., Syed F. Ali et al., Chronic Marijuana Smoke Exposure in the Rhesus Monkey IV:
Neurochemical Effects and Comparison to Acute and Chronic Exposure to Delta-9-
Tetrahydrocannabinol (THC) in Rats, 40 PHARMACOLOGY BIOCHEMISTRY & BEHAV. 677, 681
(1991) (finding no brain abnormality in animal models from cannabis smoke exposure);
Editorial, Deglamorising Cannabis, 346 LANCET 1241, 1241 (1995) ("The smoking of cannabis,
even long term, is not harmful to health."); cf Andrew R. Morral et al., Reassessing the Mari
juana Gateway Effect, 97 ADDICTION 1493, 1493-94 (2002) ("[A]vailable evidence does not
favor the marijuana gateway effect over the alternative hypothesis that marijuana and hard
drug initiation are correlated because both are influenced by individuals' heterogenous
liabilities to try drugs.").




130. See, e.g., 21 U.S.C. § 841 (b)(1)(D) (2006).
131. See Kocieniewski, supra note 124.
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Such variations mimic the confusion over methadone treatment
and heroin use. Heroin is an illegal, addictive, illicit drug,32 where-
as methadone is a legal synthetic narcotic used to treat individuals
suffering from heroin withdrawal.'33 Yet some transplant centers
equate methadone treatment with heroin use and will not place
candidates on transplant waiting lists unless they cease consump-
tion.'" Other centers will permit such placements3 5 or will allow
those on methadone maintenance programs to potentially be eli-
gible for transplantation upon completion of treatment.
C. Marijuana and Cigarettes: Inequity and Science
The inequity and inappropriate basis of medical marijuana
transplant policies is most evident when the physiological effects of
marijuana and tobacco are compared.
Both substances pose risks to organ recipients following trans-
plantation. 37 Medical marijuana users are primarily denied listing
status because of reported complications that arise when marijuana
is consumed after surgery.'" For example, invasive pulmonary as-
pergillosis ("IPA") is a rare infection that can be fatal to transplant
recipients.'39 Some marijuana contains high levels of aspergillus
and has been known to compromise immunosuppressive agents
following transplantation. '4 Although mortality rates for immuno-
compromised patients with IPA are nearly 90%, recent evidence
132. See Heroin Facts & Figures, OFFICE OF NAT'L DRUG CONTROL POLICY,
http://www.whitehousedrugpolicy.gov/drugfact/heroin/heroin_ff.html (last visited Dec.
28, 2010).
133. See Methadone, OFFICE OF NAT'L DRUG CONTROL POLICY (Apr. 2000),
http://www.whitehousedrugpolicy.gov/publications/factsht/methadone/.
134. Telephone Interview with John Pappas, Licensed Clinical Soc. Worker, Cedars-
Sinai Med. Ctr. (Nov. 11, 2008) (interview notes on file with author).
135. See id.
136. See id.
137. See Robert M. Weinrieb & Michael R. Lucey, Treatment of Addictive Behaviors in Liver
Transplant Patients, 13 LIVER TRANSPLANTATION S79, S81 (2007) (detailing the risks of to-
bacco use and noting that the risks of marijuana use remain unclear).
138. See Bramstedt et al., supra note 14, at 218-19 (stating that marijuana use post trans-
plantation can potentially wreak havoc on every physiological system in the body, and may
lead to the development of invasive pulmonary aspergillosis in kidney recipients, a potential-
ly lethal fungal infection whose only known cause is marijuana consumption after surgery);
see also Weinrieb & Lucey, supra note 137, at S81.
139. See William H. Marks et al., Successfully Treated Invasive Pulmonary Aspergillosis Associ-
ated with Smoking Marjuana in a Renal Transplant Recipient, 61 TRANSPLANTATION 1771, 1771
(1996).
140. See id. at 1773.
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suggests transplant patients can be successfully treated for the dis-
141ease.
More importantly, although touted as a rationale for rejecting
medical marijuana users from transplant candidacy, incidents of
IPA are exceedingly loW.14 2 Medical professionals speculate the in-
frequency of IPA outbreaks is attributable to the body's resilience
against this agent.1 4 ' As a result, some experts maintain transplants
should not be withheld solely on account of its use.
Tobacco use, in contrast, is responsible for a host of post-
transplant potential issues.14 5 Similar to IPA, vascular ailments and
hepatic artery thrombosis can seriously impede a liver recipient's
ability to recover.1" But in contrast to the rare event of IPA in med-
ical marijuana users, patients with a history of cigarette smoking
are more likely to incur vascular problems than non-smoking pa-
tients.14 7 In fact, it is recommended that a transplant candidate
remain smoke-free for two years prior to surgery to lessen the onset
of a vascular disorder.'4 1
Further, a smoker's prospect of long-term survival following
transplantation is also undercut by cardiac mortalities and death
from malignancies associated with smoking.149 Hence, active smok-
ers critically impact the potential success of transplants due to the
extensive harm associated with cigarette smoking.
Habituation is also a factor that needs to be taken into account
when addressing medical marijuana versus tobacco use. Patient
compliance following transplantation is a critical factor that plays
heavily into listing decisions. 1o Among other things, psychological
141. For a case study documenting the successful treatment of a renal transplant patient
who contracted aspergillosis from marijuana, see Marks et al., supra note 139. This patient
was also the first documented case of marijuana-induced invasive pulmonary aspergillosis
involving a solid organ transplant recipient.
142. For an account of an isolated report of aspergillosis contamination in a bone mar-
row recipient that was linked to marijuana, see Weinrieb & Lucey, supra note 137, at S81.
143. See Marks et al., supra note 139, at 1773.
144. See Weinrieb & Lucey, supra note 137, at S81.
145. See id.
146. See Surakit Pungpapong et al., Cigarette Smoking Is Associated with an Increased Inci-
dence of Vascular Complications After Liver Transplantation, 8 LIVER TRANSPLANTATION 582, 582
(2002).
147. See Weinrieb & Lucey, supra note 137, at S81.
148. Cf. Andrea DiMartini et al., Tobacco Use Following Liver Transplantation for Alcoholic
Liver Disease: An Underestimated Problem, 11 LIVER TRANSPLANTATION 679, 682 (2005) (noting
that doing so reduces risk of vascular complications by 58%).
149. See Karen F. Murray & Robert L. Carithers,jr., AASLD Practice Guidelines: Evaluation
of the Patient for Liver Transplantation, 41 HEPATOLOGY 1407, 1411 (2005); cf supra notes 119-
125 and accompanying text (describing the extensive harm of smoking cigarettes versus use
of medical marijuana).
150. See Murray & Carithers, supra note 149, at 1413.
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issues can severely inhibit transplantation success rates. 1' As a re-
sult, some hospitals are hesitant to consider individuals who
demonstrate addictive behavior. 112
Marijuana use has been linked to behavioral, psychological, and
social issues.1" Cannabis abuse and dependence are also reported
to be associated with an increased risk of addiction to other sub-
154y
stances. Yet treatment of marijuana-related dependencies remains
understudied. 5
A recent study showed marijuana intake rates are relevant when
analyzing psychological or physiological issues.' Quantity and
frequency correlate with dependence levels experienced by recrea-
tional users.5 7 But such results were not readily applicable to
individuals who consumed medicinal marijuana, as medical users
were not incorporated into this study.'' Researchers speculated, how-
ever, that patients who are prescribed marijuana might require large
quantities, but incur few negative side effects.'"5 Analysts also suggest-
ed that a responsible medical user could consume large amounts
without experiencing social dependence or respiratory problems."
This study also emphasized limitations on quantitative assessments
of marijuana use. Unlike packs of cigarettes, or cans of beer, marijua-
na consumption is difficult to reliably measure.'"' Factors such as
amount and potency make it difficult to produce homogenized as-
162
sessments on how the amount of marijuana consumed affects users.
In contrast to marijuana, tobacco users face well-known depend-
ency issues. Tobacco and its active ingredient nicotine have been
found to be more addictive than alcohol, cocaine, and marijua-
151. See id.
152. See Bramstedt et al., supra note 14, at 218 (describing how an Ohio facility deferred
a liver transplant candidate who presented issues of cross addictions with marijuana and
opiates to a chemical dependency treatment program, rather than granting him active list-
ing status, to prevent a potentially noncompliant patient from receiving an otherwise scarce
resource).
153. See Am. PSYCHIATRIC ASS'N, PRACTICE GUIDELINE FOR THE TREATMENT OF PATIENTS




156. See Nicole Walden & Mitch Earleywine, How High: Quantity as a Predictor of Cannabis-
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na.'63 Nicotine abuse is considered a chronic relapse disorder,'6 as
70% of smokers make more than one attempt to quit. 6 In fact,
most smokers must try to stop five to seven times before succeed-
ing.166 Individuals who suffer from nicotine dependence are also
susceptible to a host of physical issues not attendant to marijua-
167na.
Unfortunately the adverse effects of nicotine addiction are diffi-
cult to overcome, even in the context of a transplant. Research
indicates that nearly 50% of liver transplant candidates who smoke
cigarettes will continue to do so three months after surgery.'68 Over
25% of heart transplant recipients also resumed smoking following
transplantation, with an average intake rate of eleven cigarettes per
day. 169
Clearly, patients who use tobacco before surgery have a high
chance of continuing their habit after transplantation. Yet as a mat-
ter of transplantation policy, nicotine addiction through cigarette
smoking appears to have tremendous negative ramifications that
will adversely affect the success of the transplant compared to the
relatively limited impacts of medical marijuana. Accordingly, the
current system for patient selection does not reflect sound medical
or public policy.
IV. A PROPOSED POLICY
To address these concerns regarding equity and consistency, a
science-oriented model policy that relates to medical marijuana
and transplantation should be adopted by OPTN. This approach
would standardize decision-making with respect to medical mariju-
ana use and organ transplant eligibility. Here, we provide one such
policy and discuss these provisions in a subsequent section.
Facility Transplantation Policy on Candidate Substance
Use and Abuse
163. See, e.g., Denise Kandel et al., Prevalence and Demographic Correlates of Symptoms of Last
Year Dependence on Alcohol, Nicotine, Marjuana and Cocaine in the U.S. Population, 44 DRUG &
ALCOHOL DEPENDENCE 11, 23-24 (1997).
164. Am. PSYCHIATRIC Ass'N, supra note 153, at 74.
165. Id. at 73.
166. Id. at 74.
167. Cf id. at 129.
168. See DiMartini et al., supra note 148, at 681.
169. Id. at 679.
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Objective
To standardize patient placement onto the transplantation
waiting list and eligibility for organ transplant with regard to
candidate substance use and abuse. For specific clinical char-
acteristics for eligibility, please see Organ Transplant Program
policies for the specific organ, clinical criteria, and laboratory
assessment.
Definitions
"Candidate" is an individual who wishes to be placed on the
transplant waiting list for organ transplantation and is subject
to all clinical protocols associated with the Organ Transplant
Program.
"Substance Abuse" is use of an external substance by a candi-
date for non-medicinal purposes without supervision of a
treating physician.
"Substance Use" is use of an external substance by a candidate
for medicinal purposes under the supervision of a treating
physician that coordinates with the Organ Transplant Team.
Policy
To become a candidate, patients must agree to adhere to this
policy with respect to substance abuse and substance use.
Substance Abuse
1. Six-Month Abstinence. If a patient wishes to become a can-
didate, if the patient is engaged in substance abuse, including
but not limited to the use of alcohol, cigarettes, cocaine, hero-
in, and/or marijuana, the patient must agree to a period of
six months of abstinence from substance abuse before being
considered to become a candidate.
2. Random Verification. If a patient wishes to become a can-
didate, the patient agrees to be subject to random verification
of abstinence during the six months as noted in (1) above. At
the end of six months of abstinence, the patient will be evalu-
ated using the clinical protocol relevant to the organ to be
transplanted, and if he/she fulfills those criteria, shall be
placed upon the transplantation waiting list for that organ.
Patients who are listed as candidates at the end of six months
of abstinence are continuously subject to random verification
of their abstinence at all times they are on the transplantation
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waiting list and, if relevant, at all times after receiving an or-
gan transplant.
3. 'Second Chance' Policy. If a patient is engaged in sub-
stance abuse and begins the process of abstinence, if he/she
abstains for at least three months but upon random verifica-
tion between three and six months, or, after being listed as a
candidate and during random verification after such listing,
is found to be engaged in substance abuse, the patient, upon
request by the patient and approval by his/her primary care
physician, shall be eligible for a "second chance" under this
section. This "second chance" shall be a second six-month ab-
stinence period with random verifications as in the original
abstinence period. If the patient was listed as a candidate, the
patient shall be removed from the transplantation waiting list.
The patient shall be considered to be a candidate again if
he/she engages in abstinence for this second six-month ab-
stinence period. No patient will be allowed any further
potential to be a candidate if he/she fails the second six-
month abstinence or under random verification after the
second six-month abstinence is completed fails any random
verification test.
Substance Use
1. Treatment Supervision. If a patient wishes to become a
candidate and is engaged in substance use, including but not
limited to the use of medical marijuana and methadone, the
patient must agree to verification by his/her treating physi-
cian that the patient is engaged only in the use and not abuse
of the substance, and that he/she is participating completely
in any treatment program, including treatment for addiction
in a methadone maintenance program. If the patient agrees
to such treatment supervision and subject to the approval of
his/her treating physician, the patient will be evaluated using
the clinical protocol relevant to the organ to be transplanted,
and if he/she fulfills those criteria, shall be placed upon the
transplantation waiting list for that organ.
2. Random Verification. Patients who are candidates engaged
in substance use will be subject to random verification of their
compliance with physician orders and treatment associated
with their substance use as long as such use is continued.
Candidates who are engaged in substance use who are not
compliant with physician orders and treatment associated
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with their substance use upon verification shall be taken off
the transplantation waiting list. Candidates who complete sub-
stance use treatment are continuously subject to random
verification for any substance abuse, and any such substance
abuse shall be assessed according to the policy on Substance
Abuse indicated above.
3. "Second Chance" Policy. If a candidate engaged in sub-
stance use for at least three months, but upon random
verification is found to be not compliant with physician orders
and treatment associated with their substance use, the candi-
date will be taken off the transplantation waiting list. The
patient taken off the waiting list under this section, upon re-
quest by the patient and approval by his/her primary care
physician, shall be eligible for a "second chance" under this
section. The patient may be given a "second chance," and be
provided with a six-month period in which he/she must be
compliant with physician orders and treatment associated
with his/her substance use. The patient shall be considered
for candidacy again if he/she engages in substance use com-
pliant with physician orders and treatment during this period.
No patient will be allowed any further potential for candidacy
if he/she fails this "second chance" six-month period of sub-
stance use compliant with physician orders and treatment.
If the candidate engaged in substance use is found to have
engaged in substance abuse, he/she shall be subject to the
provisions of the Substance Abuse Policy, "second chance"
policy.
V. DISCUSSION OF THE PROPOSED POLICY
A. Rationalization
Several reasons are attributable to the lack of standardization in
patient selection criteria. Many hospitals want a patient evaluated
from a wide array of perspectives before listing status is even con-
sidered. 70 The need for a thorough analysis is premised upon the
cost of transplantation and the limited supply of organs."' A tre-
170. Telephone Interview with Stacy Nelson, II, Transplant Program Bus. Manager,
Centura Health Porter Adventist Hosp. (Nov. 12, 2008) [hereinafter Nelson Interview] (in-
terview notes on file with author).
171. Seeid.
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mendous amount of attention is also devoted to an individual's
likelihood of compliance of medical advice after surgery.1 2
Substance abuse has been linked to nonconformity, high recidi-
vism rates, and poor outcomes following transplantation.' While
the recognition of contraindications is structured around an im-
partial set of criteria, the process itself involves much subjectivity in
application.'7 4 The information reviewed" 5 suggests medical facili-
ties and personnel are taking a varied, and not altogether rational
approach, on how substance use and abuse plays into patient can-
didacy and listing for organ transplantation. The arbitrary
application of medical information and the intermittent use of se-
cond chance policies create tremendous potential for inequities to
be perpetuated and hidden within the decision-making process.
The resulting uneven approaches are exacerbated by the very
arbitrariness of the decision-making system itself. Each center's
own experience is likely to play a major role in policy determina-
tions, which further contributes to variations in evaluative
criteria.' 6 A hospital that has experienced successful transplanta-
tion and/or compliance rates among patients who engage in
certain high risk behavior will be more likely to approve such can-
didates for future transplantation, as opposed to those who have
not."' Hence, the irrationality of candidate choice by transplanta-
tion facilities is propagated by their own irrationality in earlier
choices, and justified by them, creating a circle of uneven candi-
dates based on questionable factors and science.
To bring the decision-making process on use of medical mariju-
ana and transplantation into the realm of medical rationality, a
policy should be structured to ensure uniformity in assessment and
judgment with respect to substance use and abuse. This approach
should focus on using reimbursement means to incentivize the ap-
propriate adoption of organ transplant allocation policy, as was
done originally in the Omnibus Budget Reconciliation Act with
OPTN policy.'7
172. See id.
173. Leslie W. Miller, Listing Criteria for Cardiac Transplantation: Results of an American So-
ciety of Transplant Physicians-National Institutes of Health Conference, 66 TRANSPLANTATION
947, 949 (1998).
174. See Nelson Interview, supra note 170.
175. See supra Sections II & III, and particularly III.B.
176. See supra Section III.
177. See Kinkopf-Zajac, supra note 9, at 513.
178. The Omnibus Budget Reconciliation Act added a section to the Social Security Act
that controlled Medicare and Medicaid reimbursement for hospitals and OPOs. See Omni-
bus Budget Reconciliation Act of 1986, Pub. L. No. 99-509, § 9318(a), 100 Stat. 1874, 2009
SPRING 2011 ] 691
University of Michigan journal of Law Reform
B. A Model Policy
As indicated above, a model policy that relates to medical mari-
juana and transplantation should be adopted by OPTN to
standardize decision-making with respect to medical marijuana
use.
Objective
To standardize patient placement onto the transplantation
waiting list and eligibility for organ transplant with regard to
candidate substance use and abuse. For specific clinical char-
acteristics for eligibility, please see Organ Transplant Program
policies for the specific organ, clinical criteria, and laboratory
assessment.
Here, the objective of the policy is stated. The focus is upon en-
suring the use of organs is standardized with relationship to
substance use and abuse to avoid the highly variable, potentially
abused process applied currently to organ allocation across the
United States. This policy expressly points the reader to clinical
protocols for data associated with particular organ states.
Next, operationalization of the policy must occur. The distinc-
tions and definitions associated with substance use versus abuse
should be distinguished by how these substances are used. This is
covered next in the policy.
Definitions
"Candidate" is an individual who wishes to be placed on the
transplant waiting list for organ transplantation and is subject
to all clinical protocols associated with the Organ Transplant
Program.
"Substance Abuse" is use of an external substance by a candi-
date for non-medicinal purposes without supervision of a
treating physician.
"Substance Use" is use of an external substance by a candidate
for medicinal purposes under the supervision of a treating
physician that coordinates with the Organ Transplant Team.
(codified as amended at 42 U.S.C. § 1320b-8 (2006)). Specifically, payment was conditioned
upon OPTN membership and compliance with its rules on transplantation. Id.
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It is apparent that a transplant facility's interpretation of the
term "abuse" is critical when evaluating candidates who use certain
substances. For example, the Revised Code of Washington State
permits the use of medical marijuana for patients diagnosed with a
terminal, or otherwise debilitating, illness."'9 Licensed medical pro-
fessionals regulate its consumption through prescriptionsiso and
discuss the benefits and risks of medical marijuana with patients
before any decision to prescribe and use the drug in the patient's
care regimen is made.'1' In this situation, medical oversight is fo-
cused and should be considered a "use."
This definition is in contrast to "abuse," which is considered by
WHO as a recreational or otherwise unsanctioned pattern of con-
sumption, irrespective of consequences." Hence, in this context,
abuse of a particular substance is consistent with perpetual or in-
termittent extreme drug use contrary to acceptable medical
practice.8 3 This, of course, also includes use of materials that are of
no clinical benefit. This distinction is therefore adopted here.
Once the distinction is made between substance abuse and sub-
stance use, substantive policy can be promulgated that focuses on
ensuring the maximum potential use and success of an organ
transplantation. Abstinence and "second chance" are the two key
issues to be addressed.
Policy
To become a candidate, patients must agree to adhere to this
policy with respect to substance abuse and substance use.
Substance Abuse
1. Six-Month Abstinence. If a patient wishes to become a can-
didate, if the patient is engaged in substance abuse, including
but not limited to the use of alcohol, cigarettes, cocaine, hero-
in, and/or marijuana, the patient must agree to a period of
179. WASH. REV. CODE § 69.51A.005 (2008) ("Some of the illnesses for which marijuana
appears to be beneficial include chemotherapy-related nausea and vomiting in cancer pa-
tients; AIDS wasting syndrome; severe muscle spasms associated with multiple sclerosis and
other spasticity disorders; epilepsy; acute or chronic glaucoma; and some forms of intracta-
ble pain.").
180. WASH. REv. CODE § 69.50.101(a)(1)-(2) (2008) (requiring administration of a con-
trolled substance to be performed by an authorized practitioner).
181. WASH. REv. CODE § 69.51A.010(3)(a)-(e) (2008) (requiring physician to advise pa-
tient about the risks and benefits of medical marijuana use before the patient can qualify for
such a prescription).
182. See WORLD HEALTH ORG., LEXICON OF ALCOHOL AND DRUG TERMS 4-5 (1994),
available at http://whqlibdoc.who.int/publications/9241544686.pdf.
183. See id.
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six months of abstinence from substance abuse before being
considered to become a candidate.
Here, substance abuse patients must adhere to a regimen that
includes a six-month abstention period from the harmful drug(s)
they are taking. This is a critical component of evaluation to ensure
they are able to avoid the abuse of drugs and are in the physical
and non-dependent condition that can promote the best chance of
success for organ transplantation.
To ensure the patient is, in fact, abstaining from substance
abuse, random verification procedures must be put into place.
2. Random Verification. If a patient wishes to become a can-
didate, the patient agrees to be subject to random verification
of abstinence during the six months as noted in 1. above. At
the end of six months of abstinence, the patient will be evalu-
ated using the clinical protocol relevant to the organ to be
transplanted, and if he/she fulfills those criteria, shall be
placed upon the transplantation waiting list for that organ.
Patients who are listed as candidates at the end of six months
of abstinence are continuously subject to random verification
of their abstinence at all times they are on the transplantation
waiting list and, if relevant, at all times after receiving an or-
gan transplant.
Here, any substance abuse patient wishing to be a candidate for
organ transplantation agrees to be subject to random verification
of his/her abstinence status. This is a crucial requirement to en-
sure compliance with the abstinence mandate and to ensure that
patients are acting for the best use of the organ itself. In addition,
so as to ensure continued abstinence, any substance abuse patient
who becomes a candidate is also expressly subject to random verifi-
cation.
If, however, the substance abuse patient does not fulfill the re-
quirements fully under this policy, but shows promise through
abstinence for at least three months, a "second chance" policy is
available.
3. "Second Chance" Policy. If a patient is engaged in sub-
stance abuse and begins the process of abstinence, if he/she is
abstinent for at least three months but upon random verifica-
tion between three and six months, or, after being listed as a
candidate and during random verification after such listing, is
found to be engaged in substance abuse, the patient, upon
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request by the patient and approval by his/her primary care
physician, shall be eligible for a "second chance" under this
section. This "second chance" shall be a second six-month ab-
stinence period with random verifications as in the original
abstinence period. If the patient was listed as a candidate, the
patient shall be removed from the transplantation waiting list.
The patient shall be considered to be a candidate again if
he/she engages in abstinence for this second six-month ab-
stinence period. No patient will be allowed any further
potential to be a candidate if he/she fails the second six-
month abstinence, or under random verification after the
second six-month abstinence is completed fails any random
verification test.
Here, a second chance is given to substance abuse patients. If
they meet the three-month cutoff, they may restart the six-month
period of abstinence. If they complete this period, and maintain
abstinence, they may become a candidate for organ transplanta-
tion. Note that this is a bright line rule: failure under this section
of the policy completely eliminates the substance abuse patient
from any consideration as a candidate for organ transplantation.
Substance Use
1. Treatment Supervision. If a patient wishes to become a
candidate and is engaged in substance use, including but not
limited to the use of medical marijuana and methadone, the
patient must agree to verification by his/her treating physi-
cian that the patient is engaged only in the use, and not abuse
of the substance, and that he/she is participating completely
in any treatment program, including treatment for addiction
in a methadone maintenance program. If the patient agrees
to such treatment supervision, and subject to the approval of
his/her treating physician, the patient will be evaluated using
the clinical protocol relevant to the organ to be transplanted,
and if he/she fulfills those criteria, shall be placed upon the
transplantation waiting list for that organ.
The critical issues here are ensuring these patients are under phy-
sician supervision, do not subject themselves to substance abuse, and
are subject to an equitable "second chance" policy. In this case, pa-
tients engaged in substance use must agree to treatment
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supervision."" Because of the medical nature of such substance use,
the abstinence provisions of the substance abuse provisions do not
apply. Hence, substance use patients are eligible for transplanta-
tion candidacy and waiting list placement if they agree to
verification of participation in treatment using the specific sub-
stance, subject to their treating physician's approval.
Verification is a necessary component in the substance use situa-
tion as in the substance abuse circumstance. This is particularly
true because substance use may become substance abuse.
2. Random Verification. Patients who are candidates engaged
in substance use will be subject to random verification of their
compliance with physician orders and treatment associated
with their substance use as long as such use is continued.
Candidates engaged in substance use who are not compliant
with physician orders and treatment associated with their sub-
stance use, upon verification, shall be taken off the
transplantation waiting list. Candidates who complete sub-
stance use treatment are continuously subject to random
verification for any substance abuse, and any such substance
abuse shall be assessed according to the policy on Substance
Abuse indicated above.
Like in the substance abuse case, random verification of the sub-
stance use patients is also important to ensure best potential use of
organs. These patients must be compliant with physician treatment
orders and treatment strategies so the optimal outcome results
when using these substances. Further, again similar to the sub-
stance abuse case, all substance use patients who become
candidates are continuously subject to random verification. How-
ever, because there is the potential for substance use to become
substance abuse, the policy expressly notes that in such a case, the
patient becomes subject to the substance abuse policy.
Finally, second chance policies for substance use are also ad-
dressed. A six-month period is used in this section as well, similar
to the substance abuse section.
3. "Second Chance" Policy. If a candidate engaged in sub-
stance use for at least three months but upon random
verification is found to be not compliant with physician orders
184. This provision would address the case of Timothy Garon. While Garon had previ-
ous issues with substance abuse, a physician monitored his use of medical marijuana at the
time of his denial. SeeJohnson, supra note 2.
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and treatment associated with their substance use, the candi-
date will be taken off the transplantation waiting list. The
patient taken off the waiting list under this section, upon re-
quest by the patient and approval by his/her primary care
physician, shall be eligible for a "second chance" under this
section. The patient may be given a "second chance" by being
provided with a six-month period in which he/she must be
compliant with physician orders and treatment associated
with his/her substance use. The patient shall be considered
for candidacy again if he/she engages in substance use com-
pliant with physician orders and treatment during this period.
No patient will be allowed any further potential for candidacy
if he/she fails this "second chance" six-month period of sub-
stance use compliant with physician orders and treatment.
If the candidate engaged in substance use is found to have
engaged in substance abuse, he/she shall be subject to the
provisions of the Substance Abuse Policy, "second chance"
policy.
In this situation, if the substance use patient is found to be non-
compliant with physician orders and treatment, he or she is given a
"second chance" through a six-month period to show compliance
to become listed as a transplantation candidate once again. How-
ever, if the patient has violated the policy and becomes engaged in
substance abuse, he or she is subject to the second chance provi-
sion in the substance abuse section.
VI. CONCLUSION
The impediments faced by transplant candidates are numerous.
It is clear that a more equitable starting point in the patient selec-
tion process should be put into place. Transplant centers across the
country are currently given boundless discretion to set their own
criteria for organ allocation allowing each to avoid transplant can-
didates based upon arbitrary medical or other characteristics. A
uniform system is clearly needed to ensure that equity is a goal the
organ transplant community is striving for, despite the challenges
of geography, population density, and other factors at play.
Of course, a unified method would not only coincide with the
rationale behind the organ allocation process as mandated by
NOTA, OPTN, and UNOS, but would also level the playing field
for candidates who have issues of substance abuse raised against
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them. Hospitals should also be compelled to codify these provi-
sions. Differentials between those who engage in substance abuse
and those under medical care who are merely using similar sub-
stances should be expressly taken into account. The result would
be another step toward equity and away from systems that inap-
propriately allocate organs to alcohol abusers and heavy cigarette
smokers over those who use medical marijuana for treatment.
A policy that takes into account issues of substance use versus
substance abuse, abstinence periods, and compliance with treat-
ment regimens, random verification, as well as potential "second
chance" allowances can yield significant benefit for patients and
the transplant efforts in this country. A uniform set of standards
creates equal expectations and requirements across facilities and
limits gaming of the system, such as multiple efforts at being
placed on a wide array of waiting lists, which drive inefficiency and
disparities.
Patient education should also be at the forefront of these efforts.
Patients who seek organ transplants need to be aware of the poten-
tial obstacles they face when attempting to be considered for an
organ transplant and waiting list placement at facilities that per-
form these activities. With clear standards on substance use, abuse,
and their associated requirements, individuals will be able to make
well-informed choices and have a clear understanding of the chal-
lenges they may be confronted with when attempting to become
candidates for transplantation.
It has been nearly twenty-five years since NOTA's enactment. Yet
this country's organ procurement and allocation efforts remain
plagued by the same injustices that existed before its passage. Or-
gan shortages, high demand, disparities, and uneven policies and
procedures lacking scientific integrity continue to prevent the
needs of many candidates from being met, particularly patients
engaged in substance use despite being under a physician's care
and treatment protocol. Medical science must be brought back in-
to the system. Policies must be created that provide for rational
selection of transplant candidates, which will ensure that the trag-
edy of Timothy Garon's death is not wasted, and the hope of a
second chance forJonathan Simchen is fulfilled.
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